Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 12/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984945 | 0.91 | TP53 (0.47) | BRD4YEATS4KCNH2 | |
| SCHEMBL6785980 | 0.83 | TDP1 (0.47) | ACSS2BRD4 | |
| SCHEMBL1417834 | 0.81 | ACSS2 (0.46) | ACSS2PDE2APDE10AGPR119 | |
| SCHEMBL7693340 | 0.80 | ACSS2 (0.38) | ACSS2BRD4 | |
| SCHEMBL7480954 | 0.78 | ESR2 (0.41) | BRD4NR1H2 | |
| SCHEMBL6784668 | 0.78 | CA2 (0.45) | BRD4 | |
| SCHEMBL30847402 | 0.77 | USP30 (0.39) | NR1H2 | |
| SCHEMBL12158 | 0.77 | USP30 (0.39) | NR1H2 | |
| SCHEMBL1418125 | 0.76 | RIPK1 (0.48) | ACSS2GPR119 | |
| SCHEMBL16460751 | 0.75 | DCTPP1 (0.36) | BRD4NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | ACSS2 1337/4885PDE2A 1318/4885PDE10A 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.